Literature DB >> 21858268

Nasal polyposis and cystic fibrosis(CF): review of the literature.

M N Feuillet-Fieux1, G Lenoir, I Sermet, C Elie, J Djadi-Prat, M Ferrec, M Magen, V Couloigner, Y Manach, B Lacour, J P Bonnefont.   

Abstract

The aim of this study was to address whether NP might be a predictive factor for severity of CF. The authors collected data from the literature on NP as a unique or associated sign in CF and reviewed the clinical and molecular aspects of CF associated with NP. CF genotypes and clinical severity in NP(+) vs. NP(-) patients were reviewed, taking into account pulmonary function, frequency of P. aeruginosa lung infection, frequency of allergy, nutritional status, and exocrine pancreatic function. The CFTR gene was also analyzed in a patient with isolated severe NP as the unique feature of CF. This review of the literature showed a `milder` phenotype in `NP+` vs. `NP-` CF patients, contrasting with a marked association between NP and `severe` CF mutations. In addition, a complex genotype was identified, associating four heterozygous variants, namely p.Q493X (a severe mutation) on the paternal allele, and p.V562I, p.A1006E, and (TG)11(T)5 (IVS8-5T) on the maternal allele, in a case of CF presenting as isolated NP. The authors speculate that genetic/environmental factors associated with NP might attenuate the functional impact of `severe` CF mutations. The overrepresentation of CF carriers among patients with isolated NP also advocates the need for CFTR molecular screening in such populations for genetic counselling purposes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21858268     DOI: 10.4193/Rhino10.225

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  8 in total

1.  Environmental allergies and respiratory morbidities in cystic fibrosis.

Authors:  Joseph M Collaco; Christopher B Morrow; Deanna M Green; Garry R Cutting; Peter J Mogayzel
Journal:  Pediatr Pulmonol       Date:  2012-11-09

2.  Functional Assays Are Essential for Interpretation of Missense Variants Associated with Variable Expressivity.

Authors:  Karen S Raraigh; Sangwoo T Han; Emily Davis; Taylor A Evans; Matthew J Pellicore; Allison F McCague; Anya T Joynt; Zhongzhou Lu; Melis Atalar; Neeraj Sharma; Molly B Sheridan; Patrick R Sosnay; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2018-05-24       Impact factor: 11.025

Review 3.  Pathogenesis and management of nasal polyposis in cystic fibrosis.

Authors:  Jochen G Mainz; Assen Koitschev
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

4.  T2R38 genotype is correlated with sinonasal quality of life in homozygous ΔF508 cystic fibrosis patients.

Authors:  Nithin D Adappa; Alan D Workman; Denis Hadjiliadis; Daniel J Dorgan; Danielle Frame; Steven Brooks; Laurel Doghramji; James N Palmer; Corrine Mansfield; Danielle R Reed; Noam A Cohen
Journal:  Int Forum Allergy Rhinol       Date:  2015-12-17       Impact factor: 3.858

5.  Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis.

Authors:  Kiranya E Tipirneni; Bradford A Woodworth
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-02-21

Review 6.  Chronic rhinosinusitis and nasal polyposis in cystic fibrosis: update on diagnosis and treatment.

Authors:  Suzie Hyeona Kang; Paulo de Tarso Roth Dalcin; Otavio Bejzman Piltcher; Raphaella de Oliveira Migliavacca
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

7.  Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes.

Authors:  Daniel M Beswick; Stephen M Humphries; Connor D Balkissoon; Matthew Strand; Eszter K Vladar; David A Lynch; Jennifer L Taylor-Cousar
Journal:  Ann Am Thorac Soc       Date:  2022-01

Review 8.  Epidemiology of chronic rhinosinusitis, selected risk factors, comorbidities, and economic burden.

Authors:  Achim Beule
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.